Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis / / by Michal Tomcik editor.
Systemic sclerosis (scleroderma) is an incurable connective tissue disease with an unclear etiology characterized by vasculopathy, dysregulation of the immune response, and progressive tissue fibrosis affecting the skin, lungs, digestive tract, heart, and kidneys. The collection of six original rese...
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | [Place of publication not identified] : : MDPI - Multidisciplinary Digital Publishing Institute,, 2023. |
Year of Publication: | 2023 |
Language: | English |
Physical Description: | 1 online resource (218 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993580991004498 |
---|---|
ctrlnum |
(CKB)5680000000300026 (NjHacI)995680000000300026 (EXLCZ)995680000000300026 |
collection |
bib_alma |
record_format |
marc |
spelling |
Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis / by Michal Tomcik editor. [Place of publication not identified] : MDPI - Multidisciplinary Digital Publishing Institute, 2023. 1 online resource (218 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on publisher supplied metadata and other sources. Systemic sclerosis (scleroderma) is an incurable connective tissue disease with an unclear etiology characterized by vasculopathy, dysregulation of the immune response, and progressive tissue fibrosis affecting the skin, lungs, digestive tract, heart, and kidneys. The collection of six original research manuscripts and five review articles included in this book highlights the most recent advances in this field and provides further elucidation of the pathogenesis, natural disease course, and treatment of this challenging disease. In English. About the Editor vii -- Preface to "Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis " ix -- Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis 1 -- Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling -- Immune-Mediated Fibrosis 5 -- Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why -- IL-6-37 -- Novel Concepts in Systemic Sclerosis Pathogenesis: Role for miRNAs 55 -- MiRNAs in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension: Markers and Effectors 73 Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin 91 -- Plasma Metabolomic Profiling Reveals Four Possibly Disrupted Mechanisms in Systemic Sclerosis 109 -- Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis 125 Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease 155 -- Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung -- Disease Patients with Normal Spirometry 173 -- Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox 185 -- Bisphosphonates for the Treatment of Calcinosis Cutis-A Retrospective Single-Center Study 199. Systemic scleroderma. Scleroderma, Systemic diagnosis Case Reports. Scleroderma, Systemic therapy Case Reports. 3-0365-6121-8 Tomcik, Michal, editor. |
language |
English |
format |
eBook |
author2 |
Tomcik, Michal, |
author_facet |
Tomcik, Michal, |
author2_variant |
m t mt |
author2_role |
TeilnehmendeR |
title |
Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis / |
spellingShingle |
Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis / About the Editor vii -- Preface to "Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis " ix -- Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis 1 -- Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling -- Immune-Mediated Fibrosis 5 -- Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why -- IL-6-37 -- Novel Concepts in Systemic Sclerosis Pathogenesis: Role for miRNAs 55 -- MiRNAs in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension: Markers and Effectors 73 Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin 91 -- Plasma Metabolomic Profiling Reveals Four Possibly Disrupted Mechanisms in Systemic Sclerosis 109 -- Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis 125 Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease 155 -- Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung -- Disease Patients with Normal Spirometry 173 -- Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox 185 -- Bisphosphonates for the Treatment of Calcinosis Cutis-A Retrospective Single-Center Study 199. |
title_full |
Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis / by Michal Tomcik editor. |
title_fullStr |
Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis / by Michal Tomcik editor. |
title_full_unstemmed |
Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis / by Michal Tomcik editor. |
title_auth |
Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis / |
title_new |
Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis / |
title_sort |
frontiers of targeted therapy and predictors of treatment response in systemic sclerosis / |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute, |
publishDate |
2023 |
physical |
1 online resource (218 pages) |
contents |
About the Editor vii -- Preface to "Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis " ix -- Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis 1 -- Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling -- Immune-Mediated Fibrosis 5 -- Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why -- IL-6-37 -- Novel Concepts in Systemic Sclerosis Pathogenesis: Role for miRNAs 55 -- MiRNAs in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension: Markers and Effectors 73 Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin 91 -- Plasma Metabolomic Profiling Reveals Four Possibly Disrupted Mechanisms in Systemic Sclerosis 109 -- Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis 125 Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease 155 -- Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung -- Disease Patients with Normal Spirometry 173 -- Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox 185 -- Bisphosphonates for the Treatment of Calcinosis Cutis-A Retrospective Single-Center Study 199. |
isbn |
3-0365-6122-6 3-0365-6121-8 |
callnumber-first |
R - Medicine |
callnumber-subject |
RC - Internal Medicine |
callnumber-label |
RC924 |
callnumber-sort |
RC 3924.5 S34 F766 42023 |
genre_facet |
Case Reports. |
illustrated |
Not Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
616 - Diseases |
dewey-full |
616.544 |
dewey-sort |
3616.544 |
dewey-raw |
616.544 |
dewey-search |
616.544 |
work_keys_str_mv |
AT tomcikmichal frontiersoftargetedtherapyandpredictorsoftreatmentresponseinsystemicsclerosis |
status_str |
n |
ids_txt_mv |
(CKB)5680000000300026 (NjHacI)995680000000300026 (EXLCZ)995680000000300026 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis / |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796652748961218560 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03116nam a2200337 i 4500</leader><controlfield tag="001">993580991004498</controlfield><controlfield tag="005">20230323151526.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230323s2023 xx o 000 0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-0365-6122-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5680000000300026</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)995680000000300026</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995680000000300026</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC924.5.S34</subfield><subfield code="b">.F766 2023</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.544</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis /</subfield><subfield code="c">by Michal Tomcik editor.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Place of publication not identified] :</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute,</subfield><subfield code="c">2023.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (218 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Systemic sclerosis (scleroderma) is an incurable connective tissue disease with an unclear etiology characterized by vasculopathy, dysregulation of the immune response, and progressive tissue fibrosis affecting the skin, lungs, digestive tract, heart, and kidneys. The collection of six original research manuscripts and five review articles included in this book highlights the most recent advances in this field and provides further elucidation of the pathogenesis, natural disease course, and treatment of this challenging disease.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">In English.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">About the Editor vii -- Preface to "Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis " ix -- Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis 1 -- Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling -- Immune-Mediated Fibrosis 5 -- Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why -- IL-6-37 -- Novel Concepts in Systemic Sclerosis Pathogenesis: Role for miRNAs 55 -- MiRNAs in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension: Markers and Effectors 73 Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin 91 -- Plasma Metabolomic Profiling Reveals Four Possibly Disrupted Mechanisms in Systemic Sclerosis 109 -- Autoantibodies as Biomarker and Therapeutic Target in Systemic Sclerosis 125 Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease 155 -- Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung -- Disease Patients with Normal Spirometry 173 -- Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox 185 -- Bisphosphonates for the Treatment of Calcinosis Cutis-A Retrospective Single-Center Study 199.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Systemic scleroderma.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Scleroderma, Systemic</subfield><subfield code="x">diagnosis</subfield><subfield code="v">Case Reports.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Scleroderma, Systemic</subfield><subfield code="x">therapy</subfield><subfield code="v">Case Reports.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-6121-8</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tomcik, Michal,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-04-15 12:29:49 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2023-02-11 21:29:23 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5343015850004498&Force_direct=true</subfield><subfield code="Z">5343015850004498</subfield><subfield code="b">Available</subfield><subfield code="8">5343015850004498</subfield></datafield></record></collection> |